

## Xromi (hydroxyurea) - New drug approval

- On April 4, 2024, the <u>FDA approved</u> Rare Disease Therapeutics' <u>Xromi (hydroxyurea)</u>, to reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age to less than 2 years, with sickle cell anemia with recurrent moderate to severe painful crises.
- Hydroxyurea is also available in a <u>tablet</u> and <u>capsule</u> formulation for sickle cell anemia.
- The effectiveness of Xromi was established based on an adequate and well-controlled study of hydroxyurea capsules in adult patients with sickle cell anemia with recurrent moderate to severe pain crises and additional pharmacokinetic data from a single-arm, open-label study of Xromi in pediatric patients aged 10 months to less than 2 years with sickle cell anemia, who were treatment naïve or had not received hydroxyurea in the 6 months prior to enrollment.
- Xromi carries a boxed warning for myelosuppression and malignancies.
- Additional warnings and precautions for Xromi include hemolytic anemia; embryo-fetal toxicity with unapproved use in adolescents and adults; vasculitic toxicities; live vaccinations; risks with concomitant use of antiretroviral drugs; macrocytosis; pulmonary toxicity; and laboratory test interference.
- The most common adverse reactions (> 33%) with Xromi use were neutropenia and thrombocytopenia.
- The recommended initial dose of Xromi is 15 mg/kg orally once daily. The dose may be increased by 5 mg/kg/day every 8 to 12 weeks until a maximum tolerated dose of 35 mg/kg/day is reached if blood counts are in an acceptable range.
  - Refer to the Xromi drug label for complete dosing and administration recommendations.
- Rare Disease Therapeutics' launch plans for Xromi are pending. Xromi will be available as a 100 mg/mL oral solution.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.